In severe cases of infection with the SARS-CoV-2 virus, the cause of COVID-19, an autoimmune reaction is responsible for deadly symptoms. In stages 2b, late pulmonary effects are seen, and in stage 3 hyperinflammation with cytokine storms occur.
Severe cases of this disease are associated with low lymphocyte counts and high levels of the cytokine, interleukin-6 (IL-6). As immunomodulators when used in low doses, both low dose naltrexone (LDN) and ketamine reduce IL-6 production, halting COVID-19 disease progression. In addition, LDN is known to have antiviral properties.
The trial, Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (SINK COVID-19) is being conducted at William Beaumonts Hospitals and information on the trial can be found at https://clinicaltrials.gov/ct2/show/NCT04365985
Resource:
Elaine A. Moore and Samantha Wilkinson. The Promise of Low Dose Naltrexone. McFarland Publishing. 2009.
www.clinicaltrials.gov
ELAINE-MOORE.COM Graves' Disease and Autoimmune Disease Education Copyrighted by Elaine Moore © 2008-2025 | All Rights Reserved. All writing and images copyrighted. Copyright Notices and Disclaimers Designed & Developed by VESWEB Using DNN 2008